PROSPECTIVE FOLLOW-UP STUDY FOR PATIENTS WHO COMPLETED STUDY ALX0681-C301 (HERCULES) TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB (POST-HERCULES)

Registry ID

ALX0681-C302

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

ABLYNX NV

Start date

2016-12-15

Completion date

2021-02-16

Last update

2016-09-30

Conditions

• UNSPECIFIED

Related clinical trials

• CONTINUING TREATMENT FOR SUBJECTS WHO HAVE PARTICIPATED IN A PRIOR PROTOCOL INVESTIGATING ELOTUZUMAB (CONTINUATION PHASE 2 ROLL-OVER PROTOCOL)
• AN OBSERVATIONAL, OPEN-LABEL, NON-RANDOMIZED STUDY TO MONTIOR FOR ADVERSE DRUG REACTIONS AMONG PATIENTS ADMINISTERED FEDORAK-MANUFACTURED [F-18]-FDG INJECTION
• INVESTIGATOR-INITIATED PHASE II STUDY OF PEMBROLIZUMAB IMMUNOLOGICAL RESPONSE EVALUATION (INSPIRE)
• EXPLORING THE EFFECTS OF PRAZOSIN ON BASAL DOPAMINE IN HEALTHY HUMANS: A [11C]-(+)-PHNO PET STUDY
• COMPARISON OF MAO-A VT BETWEEN HEALTHY MEN AND WOMEN MEASURED WITH [11C]-HARMINE PET

View on source registry